OrthoPediatrics financials
$22.76+0.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M | $59.4M | $61.6M | $61.3M | $61.1M | $52.4M | $52.7M | $54.6M | $52.8M | $44.7M | $37.6M | $40.0M |
| Gross profit | $52.4M | $43.4M | $45.1M | $45.3M | $44.0M | $38.3M | $35.6M | $40.1M | $40.8M | $32.2M | $26.7M | $31.0M |
| Gross margin | 74.3% | 73.1% | 73.2% | 73.9% | 72.1% | 73.0% | 67.5% | 73.4% | 77.3% | 72.0% | 71.0% | 77.4% |
| Operating income | -$4.1M | -$8.3M | -$8.2M | -$9.4M | -$10.7M | -$11.0M | -$14.1M | -$5.6M | -$5.7M | -$9.7M | -$5.1M | -$4.5M |
| Net income | -$7.2M | -$10.7M | -$10.1M | -$11.8M | -$7.1M | -$10.7M | -$16.1M | -$7.9M | -$6.0M | -$7.8M | -$6.7M | -$4.6M |
| Net margin | −10.2% | −18.0% | −16.4% | −19.2% | −11.6% | −20.3% | −30.5% | −14.5% | −11.4% | −17.5% | −17.8% | −11.5% |
| Diluted EPS | $-0.30 | $-0.45 | $-0.43 | $-0.50 | $-0.30 | $-0.46 | $-0.69 | $-0.34 | $-0.26 | $-0.34 | $-0.29 | $-0.20 |
| EBITDA | $1.6M | -$2.6M | $96.0K | $433.0K | -$2.5M | -$5.9M | -$4.6M | -$286.0K | -$887.0K | -$4.7M | -$8.1M | $747.0K |
| Operating cash flow | $928.0K | -$3.3M | $10.3M | -$581.0K | -$10.5M | -$4.2M | -$4.0M | -$10.3M | -$6.1M | -$6.7M | -$10.5M | -$5.7M |
| Free cash flow | -$3.1M | -$5.0M | $9.7M | -$3.4M | -$13.9M | -$8.4M | -$4.2M | -$11.7M | -$12.8M | -$13.2M | -$14.4M | -$8.7M |
| Diluted shares | 24.0M | 23.7M | 23.6M | 23.6M | 23.5M | 23.2M | 23.2M | 23.2M | 23.1M | 22.8M | 22.7M | 22.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.0M | $12.2M | $19.6M | $16.8M | $44.6M | $33.4M |
| Short-term investments | $28.9M | $36.6M | $41.3M | $40.9M | $25.6M | $25.3M |
| Total debt | $99.4M | $100.3M | $99.7M | $99.0M | $98.0M | $77.0M |
| Total assets | $511.4M | $502.2M | $508.6M | $493.5M | $503.6M | $470.3M |
| Total liabilities | $167.8M | $163.5M | $162.0M | $144.2M | $148.1M | $123.1M |
| Shareholders' equity | $343.6M | $338.7M | $346.6M | $349.3M | $355.5M | $347.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology